본문 바로가기
KERD
논문KCI 등재

Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives

김용구|신민철
대한신경정신의학회 (Korean Neuropsychiatric Association)|2020.03|PSYCHIATRY INVESTIGATION|제17권 제3호|pp. 181-192|DOI https://doi.org/10.30773/pi.2019.0236

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Major depressive disorderKetamineAntidepressant
주제분류정신과학

초록

Major depressive disorder (MDD) is a serious psychiatric illness that causes functional impairment in many people. While monoaminergic antidepressants have been used to effectively treat MDD, these antidepressants have limitations in that they have delayed onset of action and many patients remain treatment-resistant. Therefore, there is a need to develop antidepressants with a novel target, and researchers have directed their attention to the glutamatergic system. Ketamine, although developed as an anesthetic, has been found to produce an antidepressant effect at sub-anesthetic doses via N-Methyl-D-aspartic acid (NMDA) receptor blockade as well as NMDA receptor- independent pathways. A single infusion of ketamine produced rapid improvement in clinical symptoms to a considerable level and led to the resolution of serious depressive symptoms, including imminent suicidal ideation, in patients with MDD. A series of recent randomized controlled trials have provided a high level of evidence for the therapeutic efficacy of ketamine treatment in MDD and presented new insights on the dose, usage, and route of administration of ketamine as an antidepressant. With this knowledge, it is expected that ketamine treatment protocols for MDD will be established as a treatment option available in clinical practice. However, long-term safety must be taken into consideration as ketamine has abuse potential and it is associated with psychological side effects such as dissociative or psychotomimetic effects.

Abstract

Major depressive disorder (MDD) is a serious psychiatric illness that causes functional impairment in many people. While monoaminergic antidepressants have been used to effectively treat MDD, these antidepressants have limitations in that they have delayed onset of action and many patients remain treatment-resistant. Therefore, there is a need to develop antidepressants with a novel target, and researchers have directed their attention to the glutamatergic system. Ketamine, although developed as an anesthetic, has been found to produce an antidepressant effect at sub-anesthetic doses via N-Methyl-D-aspartic acid (NMDA) receptor blockade as well as NMDA receptor- independent pathways. A single infusion of ketamine produced rapid improvement in clinical symptoms to a considerable level and led to the resolution of serious depressive symptoms, including imminent suicidal ideation, in patients with MDD. A series of recent randomized controlled trials have provided a high level of evidence for the therapeutic efficacy of ketamine treatment in MDD and presented new insights on the dose, usage, and route of administration of ketamine as an antidepressant. With this knowledge, it is expected that ketamine treatment protocols for MDD will be established as a treatment option available in clinical practice. However, long-term safety must be taken into consideration as ketamine has abuse potential and it is associated with psychological side effects such as dissociative or psychotomimetic effects.

참고문헌 (115)

  1. Ferrari AJ, "Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature", Psychol Med, 43, pp.471~481 (2013)
  2. Correll CU, "Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness : a large-scale meta-analysis of 3, 211, 768 patients and 113, 383, 368 controls", World Psychiatry, 16, pp.163~180 (2017)
  3. Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
  4. Katz MM, "Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression", Neuropsychopharmacology, 29, pp.566~579 (2004)
  5. Machado-Vieira R, "Rapid onset of antidepressant action : a new paradigm in the research and treatment of major depressive disorder", J Clin Psychiatry, 69, pp.946~958 (2008)
  6. Fava M, "Definition and epidemiology of treatment-resistant depression", Psychiatr Clin North Am, 19, pp.179~200 (1996)
  7. Frazer A, "Delayed pharmacological effects of antidepressants", Mol Psychiatry, 7(Suppl 1), pp.S23~S28 (2002)
  8. Posternak MA, "Is there a delay in the antidepressant effect? A meta-analysis", J Clin Psychiatry, 66, pp.148~158 (2005)
  9. Insel TR, "The STAR*D trial : revealing the need for better treatments", Psychiatr Serv, 60, pp.1466~1467 (2009)
  10. Gelenberg AJ, "How fast are antidepressants?", J Clin Psychiatry, 61, pp.712~721 (2000)
  11. Harmer CJ, "How do antidepressants work? New perspectives for refining future treatment approaches", Lancet Psychiatry, 4, pp.409~418 (2017)
  12. Insel TR, "Cure therapeutics and strategic prevention : raising the bar for mental health research", Mol Psychiatry, 11, pp.11~17 (2006)
  13. Dragioti E, "Association of antidepressant use with adverse health outcomes : a systematic umbrella review", JAMA Psychiatry (2019)
  14. Tomasetti C, "Novel pathways in the treatment of major depression : focus on the glutamatergic system", Curr Pharm Des, 25, pp.381~387 (2019)
  15. Altamura CA, "Plasma and platelet excitatory amino acids in psychiatric disorders", Am J Psychiatry, 150, pp.1731~1733 (1993)
  16. Frye MA, "Increased anterior cingulate", medial prefrontal cortical glutamate and creatine in bipolar depression, 2007, pp.32, 2490~2499
  17. Mauri MC, "Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment", Neuropsychobiology, 37, pp.124~129 (1998)
  18. Mitani H, "Correlation between plasma levels of glutamate, alanine and serine with severity of depression", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.1155~1158 (2006)
  19. Hasler G, "Reduced prefrontal glutamate", glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy, 2007, pp.64, 193~200
  20. Abdallah CG, "Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder", Psychother Psychosom, 83, pp.298~307 (2014)
  21. Sanacora G, "From pathophysiology to novel antidepressant drugs : glial contributions to the pathology and treatment of mood disorders", Biol Psychiatry, 73, pp.1172~1179 (2013)
  22. Banasr M, "Glial pathology in an animal model of depression : reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole", Mol Psychiatry, 15, pp.501~511 (2010)
  23. Berman RM, "Antidepressant effects of ketamine in depressed patients", Biol Psychiatry, 47, pp.351~354 (2000)
  24. "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic"[URL]
  25. Moher D, "Preferred reporting items for systematic review and meta-analysis protocols(PRISMA-P)2015 statement", Syst Rev, 4, pp.1~ (2015)
  26. Trullas R, "Functional antagonists at the NMDA receptor complex exhibit antidepressant actions", Eur J Pharmacol, 185, pp.1~10 (1990)
  27. Breier A, "Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers", Am J Psychiatry, 154, pp.805~811 (1997)
  28. Moghaddam B, "Activation of glutamatergic neurotransmission by ketamine : a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex", J Neurosci, 17, pp.2921~2927 (1997)
  29. Homayoun H, "NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons", J Neurosci, 27, pp.11496~11500 (2007)
  30. Khlestova E, "The Role of GluN2CContaining NMDA Receptors in Ketamine’s Psychotogenic Action and in Schizophrenia Models", J Neurosci, 36, pp.11151~11157 (2016)
  31. Chowdhury GM, "Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects", Mol Psychiatry, 22, pp.120~126 (2017)
  32. Hardingham GE, "Synaptic versus extrasynaptic NMDA receptor signalling : implications for neurodegenerative disorders", Nat Rev Neurosci, 11, pp.682~696 (2010)
  33. Rothstein JD, "Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate", Neuron, 16, pp.675~686 (1996)
  34. Guo H, "Increased expression of the glial glutamate transporter EAAT2modulates excitotoxicity and delays the onset but not the outcome of ALS in mice", Hum Mol Genet, 12, pp.2519~2532 (2003)
  35. Miller OH, "GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine", Elife, 3, pp.e03581~ (2014)
  36. Gray JA, "Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B : single-cell NMDA receptor subunit deletion in vivo", Neuron, 71, pp.1085~1101 (2011)
  37. Wang CC, "SynGAP regulates protein synthesis and homeostatic synaptic plasticity in developing cortical networks", PLoS One, 8, pp.e83941~ (2013)
  38. Preskorn SH, "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder", J Clin Psychopharmacol, 28, pp.631~637 (2008)
  39. Ibrahim L, "A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder", J Clin Psychopharmacol, 32, pp.551~557 (2012)
  40. Boulos LJ, "Translating the Habenula-From Rodents to Humans", Biol Psychiatry, 81, pp.296~305 (2017)
  41. Yang Y, "Ketamine blocks bursting in the lateral habenula to rapidly relieve depression", Nature, 554, pp.317~322 (2018)
  42. Li N, "mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists", Science, 329, pp.959~964 (2010)
  43. Zhou W, "Ketamine-induced antidepressant effects are associated with AMPA receptorsmediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex", Eur Psychiatry, 29, pp.419~423 (2014)
  44. Liu RJ, "Ketamine strengthens CRF-activated amygdala inputs to basal dendrites in mPFC layer V Pyramidal cells in the prelimbic but not infralimbic subregion, a key suppressor of stress responses", Neuropsychopharmacology, 40, pp.2066~2075 (2015)
  45. Stone JM, "Ketamine effects on brain GABA and glutamate levels with 1HMRS : relationship to ketamine-induced psychopathology", Mol Psychiatry, 17, pp.664~665 (2012)
  46. Jourdi H, "Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation", J Neurosci, 29, pp.8688~8697 (2009)
  47. Takei N, "Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites", J Neurosci, 24, pp.9760~9769 (2004)
  48. Bjorkholm C, "BDNF-a key transducer of antidepressant effects", Neuropharmacology, 102, pp.72~79 (2016)
  49. Li N, "Glutamate Nmethyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure", Biol Psychiatry, 69, pp.754~761 (2011)
  50. Gass N, "Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat", Neuropsychopharmacology, 39, pp.895~906 (2014)
  51. Murrough JW, "Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder", Transl Psychiatry, 5, pp.e509~ (2015)
  52. Sutton MA, "Regulation of dendritic protein synthesis by miniature synaptic events", Science, 304, pp.1979~1983 (2004)
  53. Sutton MA, "Miniature neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis", Cell, 125, pp.785~799 (2006)
  54. Nosyreva E, "Acute suppression of spontaneous neurotransmission drives synaptic potentiation", J Neurosci, 33, pp.6990~7002 (2013)
  55. Autry AE, "NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses", Nature, 475, pp.91~95 (2011)
  56. Gideons ES, "Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses", Proc Natl Acad Sci U S A, 111, pp.8649~8654 (2014)
  57. Newport DJ, "Ketamine and other NMDA antagonists : early clinical trials and possible mechanisms in depression", Am J Psychiatry, 172, pp.950~966 (2015)
  58. Zarate CA Jr, "A double-blind, placebo-controlled study of memantine in the treatment of major depression", Am J Psychiatry, 163, pp.153~155 (2006)
  59. Lenze EJ, "Memantine for late-life depression and apathy after a disabling medical event : a 12-week, double-blind placebo-controlled pilot study", Int J Geriatr Psychiatry, 27, pp.974~980 (2012)
  60. Zarate CA Jr, "A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression", Biol Psychiatry, 74, pp.257~264 (2013)
  61. Sanacora G, "Adjunctive Lanicemine(AZD6765)in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants : A Randomized, Placebo-Controlled Study", Neuropsychopharmacology, 42, pp.844~853 (2017)
  62. Zarate CA Jr, "Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression", Biol Psychiatry, 72, pp.331~338 (2012)
  63. Zanos P, "NMDAR inhibition-independent antidepressant actions of ketamine metabolites", Nature, 533, pp.481~486 (2016)
  64. Yamaguchi JI, "(2R, 6R)-Hydroxynorketamine is not essential for the antidepressant actions of(R)-ketamine in mice", Neuropsychopharmacology, 43, pp.1900~1907 (2018)
  65. Zarate CA Jr, "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression", Arch Gen Psychiatry, 63, pp.856~864 (2006)
  66. Petty F, "Benzodiazepines as antidepressants:does GABA play a role in depression?", Biol Psychiatry, 38, pp.578~591 (1995)
  67. Murrough JW, "Antidepressant efficacy of ketamine in treatment-resistant major depression : a two-site randomized controlled trial", Am J Psychiatry, 170, pp.1134~1142 (2013)
  68. Diazgranados N, "A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression", Arch Gen Psychiatry, 67, pp.793~802 (2010)
  69. Zarate CA Jr, "Replication of ketamine’s antidepressant efficacy in bipolar depression : a randomized controlled add-on trial", Biol Psychiatry, 71, pp.939~946 (2012)
  70. Sos P, "Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression", Neuro Endocrinol Lett, 34, pp.287~293 (2013)
  71. Hu YD, "Single i. v. ketamine augmentation of newly initiated escitalopram for major depression : results from a randomized, placebo-controlled 4-week study", Psychol Med, 46, pp.623~635 (2016)
  72. Goldberg ME, "Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome", Pain Physician, 8, pp.175~179 (2005)
  73. Lenze EJ, "Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression : A pilot randomised controlled trial", World J Biol Psychiatry, 17, pp.230~238 (2016)
  74. McGirr A, "A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes", Psychol Med, 45, pp.693~704 (2015)
  75. Fava M, "Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)", Mol Psychiatry (2018)
  76. Diamond PR, "Ketamine infusions for treatment resistant depression : a series of 28 patients treated weekly or twice weekly in an ECT clinic", J Psychopharmacol, 28, pp.536~544 (2014)
  77. Ionescu DF, "Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation : A randomized, double blind, placebo controlled trial", J Affect Disord, 243, pp.516~524 (2019)
  78. Singh JB, "A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression", Am J Psychiatry, 173, pp.816~826 (2016)
  79. Phillips JL, "Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression : A Randomized Controlled Trial", Am J Psychiatry, 176, pp.401~409 (2019)
  80. Weksler N, "Nasal ketamine for paediatric premedication", Can J Anaesth, 40, pp.119~121 (1993)
  81. Diaz JH, "Intranasal ketamine preinduction of paediatric outpatients", Paediatr Anaesth, 7, pp.273~278 (1997)
  82. Opler LA, "Ameliorating treatment-refractory depression with intranasal ketamine : potential NMDA receptor actions in the pain circuitry representing mental anguish", CNS Spectr, 21, pp.12~22 (2016)
  83. Lapidus KA, "A randomized controlled trial of intranasal ketamine in major depressive disorder", Biol Psychiatry, 76, pp.970~976 (2014)
  84. Daly EJ, "Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression : A Randomized Clinical Trial", JAMA Psychiatry, 75, pp.139~148 (2018)
  85. Daly EJ, "Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial", JAMA Psychiatry (2019)
  86. Popova V, "Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression : a randomized double-blind active-controlled study", Am J Psychiatry, 176, pp.428~438 (2019)
  87. Ochs-Ross R, "Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression", Am J Geriatr Psychiatry, 27, pp.S139~S140 (2019)
  88. Sokero TP, "Suicidal ideation and attempts among psychiatric patients with major depressive disorder", J Clin Psychiatry, 64, pp.1094~1100 (2003)
  89. De Berardis D, "Eradicating suicide at its roots : preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors", Int J Mol Sci, 19 (2018)
  90. Price RB, "Does ketamine have anti-suicidal properties? Current status and future directions", CNS Drugs, 29, pp.181~188 (2015)
  91. Price RB, "Effects of ketamine on explicit and implicit suicidal cognition : a randomized controlled trial in treatment-resistant depression", Depress Anxiety, 31, pp.335~343 (2014)
  92. Murrough JW, "Ketamine for rapid reduction of suicidal ideation : a randomized controlled trial", Psychol Med, 45, pp.3571~3580 (2015)
  93. Grunebaum MF, "Ketamine for rapid reduction of suicidal thoughts in major depression : a midazolam-controlled randomized clinical trial", Am J Psychiatry, 175, pp.327~335 (2018)
  94. Canuso CM, "Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide : results of a double-blind, randomized, placebo-controlled study", Am J Psychiatry, 175, pp.620~630 (2018)
  95. Chen MH, "Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression : A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study", J Affect Disord, 259, pp.15~20 (2019)
  96. Krystal JH, "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses", Arch Gen Psychiatry, 51, pp.199~214 (1994)
  97. Morgan CJ, "Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers", Neuropsychopharmacology, 29, pp.208~218 (2004)
  98. Wan LB, "Ketamine safety and tolerability in clinical trials for treatmentresistant depression", J Clin Psychiatry, 76, pp.247~252 (2015)
  99. Kishimoto T, "Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression : a meta-analysis of efficacy, safety and time trajectories", Psychol Med, 46, pp.1459~1472 (2016)
  100. Fond G, "Ketamine administration in depressive disorders: a systematic review and meta-analysis", Psychopharmacology(Berl), 231, pp.3663~3676 (2014)
  101. Short B, "Side-effects associated with ketamine use in depression : a systematic review", Lancet Psychiatry, 5, pp.65~78 (2018)
  102. Anand A, "Attenuation of the neuropsychiatric effects of ketamine with lamotrigine : support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists", Arch Gen Psychiatry, 57, pp.270~276 (2000)
  103. Huang MC, "Potential benefit of lamotrigine in managing ketamine use disorder", Med Hypotheses, 87, pp.97~100 (2016)
  104. Williams NR, "Attenuation of antidepressant effects of ketamine by opioid receptor antagonism", Am J Psychiatry, 175, pp.1205~1215 (2018)
  105. Morgan CJ, "Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing : a 1-year longitudinal study", Addiction, 105, pp.121~133 (2010)
  106. Liu Y, "Ketamine abuse potential and use disorder", Brain Res Bull, 126, pp.68~73 (2016)
  107. Sassano-Higgins S, "A review of ketamine abuse and diversion", Depress Anxiety, 33, pp.718~727 (2016)
  108. Li JH, "To use or not to use : an update on licit and illicit ketamine use", Subst Abuse Rehabil, 2, pp.11~20 (2011)
  109. Murrough JW, "Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression : a randomized controlled trial", Neuropsychopharmacology, 40, pp.1084~1090 (2015)
  110. Gorlyn M, "Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects", J Neural Transm(Vienna), 115, pp.1213~1219 (2008)
  111. Monteggia LM, "Antidepressant actions of ketamine : from molecular mechanisms to clinical practice", Curr Opin Neurobiol, 30, pp.139~143 (2015)
  112. Ionescu DF, "Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine", J Clin Psychiatry, 75, pp.e932~e938 (2014)
  113. Salloum NC, "Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression", Depress Anxiety, 36, pp.235~243 (2019)
  114. Wilkinson ST, "Cognitive behavior therapy may sustain antidepressant effects of intravenous Ketamine in treatment-resistant depression", Psychother Psychosom, 86, pp.162~167 (2017)
  115. Bahr R, "Intranasal Esketamine(SpravatoTM)for use in treatment-resistant depression in conjunction with an oral antidepressant", P T, 44, pp.340~375 (2019)

관련 논문AI추천

Ketamine의 속효성 항우울효과와 임상 적용김용구, 신철민대한신경정신의학회 · 신경정신의학2018 · 제57권 제2호The Role of Glutamate Underlying Treatment-resistant DepressionJa Wook Koo, Jeongseop Kim, Seung-Hwan Lee, Tae-Eun Kim대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제3호케타민의 항우울 효과와 임상적 적용김병수대한생물치료정신의학회 · 생물치료정신의학2020 · 제26권 제2호우울증에서 에스케타민의 임상 적용: 서술적 문헌 고찰이화영, 최범성대한생물정신의학회 · 생물정신의학2024 · 제31권 제2호Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical PracticeAlessandro Serretti대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2025 · 제23권 제4호Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis박원명, Chi-Un Pae, Hae-Ran Na, Hyun Kook Lim, Nak-Young Kim, Sheng Min Wang, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제2호

이 간행물의 다른 논문 (11건)

Major Depressive Disorder: Current Advances and Paradigm ShiftsYong-Ku Kimpp. 179-180Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical VariablesGiampaolo Perna, Alessandra Alciati, Silvia Daccò, Massimiliano Grassi, Daniela Caldirolapp. 193-206Understanding the Complex of Suicide in Depression: from Research to ClinicsAlessandro Valchera, Maurizio Pompili, Giovanni Martinotti, Silvia Fraticelli, Roberto Latini, Carmine Tomasetti, Raffaella La Rovere, Domenico De Berardis, Gianluca Serafini, Laura Orsolini, Umberto Volpe, Michele Fornaro, Sabatino Trotta, Federica Vellante, Marco Alessandrini, Massimo Di Giannantoniopp. 207-221The Hypothesis on the Prediction of Treatment Response with Buspirone Augmentation along with Serotonergic Antidepressant in Patients with Major Depressive Disorder Using Loudness Dependence of Auditory Evoked Potentials: Two Cases and Review of the Literature for EvidenceYoung-Min Parkpp. 222-224Neural Mechanisms in Eating Behaviors: A Pilot fMRI Study of Emotional ProcessingT. García-Saiz, Jeffrey C.L. Looi, E. Via Virgili, M. Rincón Zamorano, Laura de Anta Tejado, Helena Trebbau López, Jose Luis Carrasco Perera, Marina Díaz-Marsá, Rosa M. Molina-Ruizpp. 225-236
원문 보기